Insider · CIK 0002041719
Ruxandra Draghia-Akli
Files at NVAX (NOVAVAX INC). First filing -, latest -.
In brief
Ruxandra Draghia-Akli files SEC Form 4 as officer at NVAX (NOVAVAX INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ruxandra Draghia-Akli has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 27, 2026 | NVAX NOVAVAX, INC. | 21,383 0.01% of outstanding | $235k | May 27, 2026 | $296k |
| May 7, 2026 | NVAX NOVAVAX, INC. | 30,000 0.02% of outstanding | $296k | May 7, 2026 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | NVAX NOVAVAX INC | AGrant or award Non-Statutory Stock Option NQderivative | +139,500 | $0.00 | $0 | 139,500 | Mar 9, 2026 |
| Mar 3, 2026 | NVAX NOVAVAX INC | MOption exercise Common Stock | +26,667 | $0.00 | $0 | 34,876 | Mar 5, 2026 |
| Mar 3, 2026 | NVAX NOVAVAX INC | FTax withholding Common Stock | -11,313 | $9.49 | $107k | 23,563 | Mar 5, 2026 |
| Mar 2, 2026 | NVAX NOVAVAX INC | AGrant or award Restricted Stock Unitsderivative | +93,000 | $0.00 | $0 | 101,000 | Mar 5, 2026 |
| Mar 2, 2026 | NVAX NOVAVAX INC | AGrant or award Non-Statutory Stock Opotion NQderivative | +139,500 | $9.09 | $1.3M | 139,500 | Mar 5, 2026 |
| Mar 3, 2026 | NVAX NOVAVAX INC | DDisposition to issuer Restricted Stock Unitsderivative | -26,667 | $0.00 | $0 | 53,333 | Mar 5, 2026 |
| Nov 11, 2025 | NVAX NOVAVAX INC | MOption exercise Common Stock | +14,257 | $0.00 | $0 | 14,257 | Nov 13, 2025 |
| Nov 11, 2025 | NVAX NOVAVAX INC | FTax withholding Common Stock | -6,048 | $7.40 | $45k | 8,209 | Nov 13, 2025 |
| Nov 11, 2025 | NVAX NOVAVAX INC | DDisposition to issuer Restricted Stock Unitsderivative | -14,257 | $0.00 | $0 | 28,513 | Nov 13, 2025 |
| Mar 3, 2025 | NVAX NOVAVAX INC | AGrant or award 2025 Non-statutory Stock Option NQderivative | +120,000 | $7.87 | $944k | 120,000 | Mar 5, 2025 |
| Mar 3, 2025 | NVAX NOVAVAX INC | AGrant or award 2025 Restricted Stock Units RSUderivative | +80,000 | $0.00 | $0 | 80,000 | Mar 5, 2025 |
| Nov 11, 2024 | NVAX NOVAVAX INC | AGrant or award Stock Option (Right to Buy)derivative | +64,150 | $9.01 | $578k | 64,150 | Nov 13, 2024 |
| Nov 11, 2024 | NVAX NOVAVAX INC | AGrant or award Restricted Stock Unitsderivative | +42,770 | $0.00 | $0 | 42,770 | Nov 13, 2024 |
Questions about Ruxandra Draghia-Akli
Answered from the filings on this page, as of the latest one.
Is Ruxandra Draghia-Akli buying or selling?
Ruxandra Draghia-Akli has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ruxandra Draghia-Akli's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ruxandra Draghia-Akli has 0.
Where does Ruxandra Draghia-Akli file Form 4?
Ruxandra Draghia-Akli has filed Form 4 at NVAX (NOVAVAX INC) as EVP, Research & Development. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.